Therapeutic human albumin having a low aluminium binding capacity
AssigneeGrupo Grifols, S.A.
InventorsPere Ristol Debart, David Camarero Torrecillas
Life of this patent
Estimating the term…
Abstract
There is described a therapeutic human albumin having a very low capacity for the absorption of aluminium, during storage in a glass receptacle, wherein the final composition of the albumin solution adjusted to be stable and isotonic at a concentration of 5, 20 or 25% of protein in an aqueous medium, preferably, or to any other therapeutic concentration acceptable for intravenous administration, has a citrate content in the final albumin composition equal to or less than 0.5 mM (millimolar) and, preferably, less than 0.037 mM (millimolar).
Claims7
A therapeutic package comprising a glass container for sterile solutions containing therein an aqueous human albumin composition which comprises human albumin at a concentration acceptable for intravenous administration, wherein said composition comprises less than 0.12 millimolar citrate, wherein said human albumin composition attains a concentration of aluminum of not greater than 100 parts per billion after storage at 45.degree. C. for thirty days in said glass container.
Dependencies are inferred from the claim text.